{
  "abstract": "Background: Comparative real-world evidence for camrelizumab plus famitinib versus PD-1 inhibitor plus platinum- and/or taxane-based chemotherapy with or without bevacizumab in persistent, recurrent, or metastatic cervical cancer remains limited. This study evaluated the clinical outcomes and safety of these strategies. Methods: This single-center retrospective cohort study included 111 patients treated between July 2023 and October 2025; 42 received camrelizumab plus famitinib and 69 received the control regimen. Progression-free survival (PFS) was the primary endpoint. Overall survival (OS), tumor response, treatment-related adverse events (TRAEs), propensity score-based robustness analyses, and exploratory post-baseline marker analyses were also assessed. Results: Full-cohort and propensity score-matched Kaplan-Meier analyses showed longer PFS with camrelizumab plus famitinib (p = 0.026 and p = 0.004, respectively). Treatment-effect estimates also favored camrelizumab plus famitinib in unadjusted Cox (p = 0.028), residual imbalance-adjusted Cox (p = 0.041), 1:1 propensity score-matched Cox (p = 0.010), trimmed inverse probability of treatment weighting Cox (p = 0.006), and overlap-weighted Cox analyses (p = 0.005), whereas the prespecified baseline-adjusted Cox model was not statistically significant (p = 0.062). Disease control rate was higher (p = 0.038), grade 3–5 myelosuppression was lower (p = 0.010), and hypertension was higher (p = 0.023) with camrelizumab plus famitinib. OS did not differ significantly. Liver metastasis (p = 0.001) and higher baseline neutrophil-to-lymphocyte ratio (p = 0.037) were associated with shorter PFS. Conclusions: Camrelizumab plus famitinib showed a favorable PFS signal across several analyses, higher disease control, and a distinct safety profile, while the primary baseline-adjusted estimate and OS remained statistically non-significant.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Radiation Oncology, The Friendship Hospital of Ili Kazakh Autonomous Prefecture, 58 Chongqing Road, Yining, Xinjiang Uygur Autonomous Region, China"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 8,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Xiaojing Liu"
    },
    {
      "affs": [
        0
      ],
      "name": "Beibei Hua"
    },
    {
      "affs": [
        0
      ],
      "name": "Yang Xia"
    },
    {
      "affs": [
        0
      ],
      "name": "Huijie Huang"
    },
    {
      "affs": [
        0
      ],
      "name": "Areai Hakewati"
    },
    {
      "affs": [
        0
      ],
      "name": "Zeze Jin"
    },
    {
      "affs": [
        0
      ],
      "name": "Tumaris Halifu"
    },
    {
      "affs": [
        0
      ],
      "name": "Zaihua Xu",
      "orcid": "0009-0007-7017-5753"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/2nbyw9a5y6190.bib",
  "cited_by": 0,
  "doi": "10.32604/or.2026.088774",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13732342/",
  "id": "2nbyw9a5y6190",
  "issns": [
    "0965-0407",
    "1555-3906"
  ],
  "landing_url": "https://doi.org/10.32604/or.2026.088774",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Article"
    ],
    [
      "openalex",
      "2729|Endometrial and Cervical Cancer Treatments"
    ]
  ],
  "openalex": "W7223674945",
  "pdf_url": "https://www.techscience.com/or/online/detail/28777/TSP_OR_88774.pdf",
  "pmcid": "PMC13732342",
  "pmid": "42985504",
  "published": "2026-10-28",
  "publisher": "Tech Science Press",
  "ris": "https://research.draconitic.com/paper/2nbyw9a5y6190.ris",
  "sources": [
    {
      "first_seen": "2026-11-08T12:22:20Z",
      "native_id": "PMC13732342",
      "source": "pmc",
      "url": "https://doi.org/10.32604/or.2026.088774"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2729|Endometrial and Cervical Cancer Treatments",
      "subfield": "reproductive-child"
    }
  ],
  "title": "Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer",
  "title_text": "Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer",
  "type": "peer-reviewed",
  "updated_at": "2026-11-08T12:22:20Z",
  "url": "https://research.draconitic.com/paper/2nbyw9a5y6190",
  "venue": "Oncology Research",
  "versions": []
}